Callum Wilson

Dr. Callum Wilson


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
DVDanique van Vliet
Danique van Vliet
AWAnnemiek van Wegberg
Annemiek van Wegberg
KAKirsten Ahring
Kirsten Ahring
MBMiroslaw Bik-Multanowski
Miroslaw Bik-Multanowski
NBNenad Blau
Nenad Blau
FSFrancjan J. Van Spronsen
Francjan J. Van Spronsen
Phenylketonuria (PKU) is often considered as the classical example of a genetic disorder in which severe symptoms can nowadays successfully be prevented by early diagnosis and treatment. In contrast, untreated or late-treated PKU is known to result in severe intellectual disability, seizures, and behavioral disturbances. Rarely, however, untreated or late-diagnosed PKU patients with high plasma phenylalanine concentrations have been reported to escape from intellectual disability. The present study aimed to review published cases of such PKU patients. To this purpose, we conducted a literature search in PubMed and EMBASE up to 8th of September 2017 to identify cases with 1) PKU diagnosis and start of treatment after 7 years of age; 2) untreated plasma phenylalanine concentrations ≥1200 μmol/l; and 3) IQ ≥80. Literature search, checking reference lists, selection of articles, and extraction of data were performed by two independent researchers. In total, we identified 59 published cases of patients with late-diagnosed PKU and unexpected favorable outcome who met the inclusion criteria. Although all investigated patients had intellectual functioning within the normal range, at least 19 showed other neurological, psychological, and/or behavioral symptoms. Based on the present findings, the classical symptomatology of untreated or late-treated PKU may need to be rewritten, not only in the sense that intellectual dysfunction is not obligatory, but also in the sense that intellectual functioning does not (re)present the full picture of brain damage due to high plasma phenylalanine concentrations. Further identification of such patients and additional analyses are necessary to better understand these differences between PKU patients.

27 May 2003 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
CWCallum Wilson
Callum Wilson
COClaudio Priore Oliva
Claudio Priore Oliva
FMFranco Maggi
Franco Maggi
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌
SCSebastiano Calandra
Sebastiano Calandra

25 October 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
DVDanique van Vliet
Danique van Vliet
AWAnnemiek van Wegberg
Annemiek van Wegberg
KAKirsten Ahring
Kirsten Ahring
MBMiroslaw Bik-Multanowski
Miroslaw Bik-Multanowski
KCKari Casas
Kari Casas
FSFrancjan J. Van Spronsen
Francjan J. Van Spronsen
Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations.

1 July 2005 in The Journal of Pediatrics
Verified
Journal Article
Closed access
CWCallum Wilson
Callum Wilson
MMMichael Myer
Michael Myer
BDBrian A. Darlow
Brian A. Darlow
TSThorsten Stanley
Thorsten Stanley
GTGlen Thomson
Glen Thomson
DTDavid R. Thorburn
David R. Thorburn

9 March 2021 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
SAStylianos E Antonarakis
Stylianos E Antonarakis
AHAleš Holoubek
Aleš Holoubek
MRMelivoia Rapti
Melivoia Rapti
JRJesse Rademaker
Jesse Rademaker
JMJenny Meylan
Jenny Meylan
FSFederico A Santoni
Federico A Santoni
Knobloch syndrome is an autosomal recessive phenotype mainly characterized by retinal detachment and encephalocele caused by biallelic pathogenic variants in the COL18A1 gene. However, there are patients clinically diagnosed as Knobloch syndrome with unknown molecular etiology not linked to COL18A1. We studied an historical pedigree (published in 1998) designated as KNO2 (Knobloch type 2 syndrome with intellectual disability, autistic behavior, retinal degeneration, encephalocele). Whole exome sequencing of the two affected siblings and the normal parents resulted in the identification of a PAK2 non-synonymous substitution p.(Glu435Lys) as a causative variant. The variant was monoallelic and apparently de novo in both siblings indicating a likely germ-line mosaicism in one of the parents; the mosaicism, however, could not be observed after deep sequencing of blood parental DNA. PAK2 encodes a member of a small group of serine/threonine kinases; these P21-activating kinases (PAKs) are essential in signal transduction and cellular regulation (cytoskeletal dynamics, cell motility, death and survival signaling and cell cycle progression). Structural analysis of the PAK2 p.(Glu435Lys) variant that is located in the kinase domain of the protein predicts a possible compromise in the kinase activity. Functional analysis of the p.(Glu435Lys) PAK2 variant in transfected HEK293T cells results in a partial loss of the kinase activity. PAK2 has been previously suggested as an autism-related gene. Our results show that PAK2-induced phenotypic spectrum is broad and not fully understood. We conclude that the KNO2 syndrome in the studied family is dominant and caused by a deleterious variant in the PAK2 gene.

27 June 2005 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
VHVivienne M. Homer
Vivienne M. Homer
PGPeter M. George
Peter M. George
STStephen Du Toit
Stephen Du Toit
JDJames S. Davidson
James S. Davidson
CWCallum Wilson
Callum Wilson